Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...
Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...
ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...
Immutep Limited (IMMP) is a promising biotech stock with a strong pipeline and solid financial foundation, making it a buy ...
Stocktwits on MSN1h
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of OptimismImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...
Sidney, a book developer and publisher, announced today the publication of YOU ARE THE DOCTOR: The Importance of a Team Approach in Cancer Treatment by the late Susan Finlay Dunbar, MD. A unique ...
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
Today, the Susan and Charles Berghoff Foundation announced the public release of its award-winning documentary film, Sue's Story: A Journey with Lewy Body Dementia, in recognition of World Lewy Body ...
As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback